Loading...
Docoh
Log in Free sign up

Bellerophon Therapeutics (BLPH)

News

From Benzinga Pro
Recap: Bellerophon Therapeutics Q1 Earnings
11 May 22
Earnings
Bellerophon Therapeutics (NASDAQ:BLPH) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Bellerophon Therapeutics Q1 EPS $(0.59) Down From $(0.58) YoY
11 May 22
Earnings, News
Bellerophon Therapeutics (NASDAQ:BLPH) reported quarterly losses of $(0.59) per share. This is a 1.72 percent decrease over losses of $(0.58) per share from the same period last year.
90 Biggest Movers From Yesterday
10 May 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers
Stocks That Hit 52-Week Lows On Thursday
10 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Thursday, 166 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
8 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Tuesday's session saw 729 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Monday
7 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 524 stocks hit new 52-week lows.

Press releases

From Benzinga Pro
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
11 May 22
Earnings, Press Releases
WARREN, N.J., May 11, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for
Bellerophon Provides Clinical Program Update and Reports Full-Year 2021 Financial Results
31 Mar 22
Earnings, Press Releases
WARREN, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for